Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824

Molecular Cancer Therapeutics

Volumn 4, Issue 9, 2005, Pages 1311-1319

  Chen, Liwei ^a,b   Meng, Songshu ^a,b   Wang, Hai ^a,b   Bali, Purva ^a,b   Bai, Wenlong ^b   Li, Benyi ^c   Atadja, Peter ^d   Bhalla, Kapil N ^a,b   Wu, Jie ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ACTIN; ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; BUTYRIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEASOME; PROTEIN KINASE B; PROTEIN P21; PROTEIN P85; RAF PROTEIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANDROGEN; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; MACROCYCLIC LACTAM; PROTEIN SERINE THREONINE KINASE; RIFABUTIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISSOCIATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MALE; MUTANT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN PROCESSING; WILD TYPE; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOPRECIPITATION; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; WESTERN BLOTTING;

ACETYLATION; ANDROGENS; APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; IMMUNOPRECIPITATION; LACTAMS, MACROCYCLIC; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RIFABUTIN; TUMOR CELLS, CULTURED;

EID: 33644696512     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0287     Document Type: Article

References (50)

1. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93: 1687-97.
2. Culig Z, Hobisch A, Hittmair A, et al. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998;35:63-70.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-9.
4. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
5. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62:1496-502.
6. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
7. Eder IE, Hoffmann J, Rogatsch H, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002;9:117-25.
8. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419-24.
9. Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17-demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 2002;8:962-6.
10. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp7O-based chaperone machinery. Exp Biol Mad (Maywood) 2003;228:111-33.
11. Fang Y, Fliss AE, Robins DM, Caplan AJ. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996;271: 28697-702.
12. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003;30:709-16.
13. Vanaja DK, Mitchell SH, Toft DO, Young CY. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 2002;7:55-64.
14. Solit DB, Zheng FF, Drobnjak M, at al. 17-Ailylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
15. Enmon R, Yang WH, Ballangrud AM, at al. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003;63:8393-9.
16. Bagatell R, Khan 0, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 2001;7:2076-84.
17. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425: 407-10.
18. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-8.
19. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001;27:260-4.
20. Marks PA. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004;3:534-5.
21. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1: 194-202.
22. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13.
23. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63: 5126-35.
24. Fuino L, Bali P, Wittmann S, at al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971 -84.
25. Remiszewski SW. The discovery of NVP-LA0824: from concept to clinic. Curr Med Chem 2003; 10:2393-402.
26. Remiszewski SW, Sambucetti LC, Bair KW, at al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[(2-hydroxyethyl) [2-(l H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-24.
27. Atadja P, Gao L, Kwon P, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004;64:689-95.
28. Catley L, Weisberg E, Tai YT, at al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-22.
29. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305: 399-401.
30. Deininger MW, Druker BJ. SRCircumventing imatinib resistance. Cancer Cell 2004;6:108-10.
31. Butler LM, Agus DB, Scher HI, at al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
32. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
33. Thalmann GN, Anezinis PE, Chang SM, at al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
34. Klein KA, Reiter RE, Redula J, at al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Mad 1997;3:402-8.
35. Liao X, Thrasher JB, Pelling J, Holzbeierlein J, Sang QX, Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003; 144:1656-63.
36. Cunnick JM, Dorsey JF, Standley T, et al. Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem 1998; 273:14468-75.
37. Ren Y, Meng S, Mai L, Zhao ZJ, Jove R, Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 2004;279:8497-505.
38. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000;60: 3127-31.
39. Wu J, Lau LF, Sturgill TW. Rapid deactivation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP-1. FEES Lett 1994;353:9-12.
40. Guardiola AR, Yao TP. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 2002;277:3350-6.
41. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003;23:8563-75.
42. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-14.
43. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007.
44. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004;23:5175-84.
45. Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
46. Calvo BF, Levine AM, Marcos M, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003;9:1087-97.
47. Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6841-5.
48. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Mad 1999;5: 280-5.
49. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/ neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6:517-27.
50. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.